A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 591-600

  Szego, Éva M ^a   Gerhardt, Ellen ^a   Kermer, Pawel ^a,b   Schulz, Jörg B ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

Author keywords

synuclein; Dopamine; L DOPA; MPTP; Regeneration; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA SYNUCLEIN A30P; BENSERAZIDE; LEVODOPA; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG INHIBITION; GENE EXPRESSION PROFILING; MALE; MOUSE; NERVE REGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; SUBSTANTIA NIGRA PARS COMPACTA; TREATMENT RESPONSE; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DOPAMINERGIC NEURONS; LEVODOPA; MALE; MICE; MICE, KNOCKOUT; NERVE REGENERATION; PARKINSONIAN DISORDERS;

EID: 81955164177     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.09.017     Document Type: Article

References (50)

1. Alafuzoff I., Parkkinen L., Al-Sarraj S., Arzberger T., Bell J., Bodi I., et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe consortium. J. Neuropathol. Exp. Neurol. 2008, 67:125-143.
2. Braissant O., Henry H., Villard A.M., Zurich M.G., Loup M., Eilers B., et al. Ammonium-induced impairment of axonal growth is prevented through glial creatine. J. Neurosci. 2002, 22:9810-9820.
3. Calabrese V., Mancuso C., Ravagna A., Perluigi M., Cini C., De Marco C., et al. In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J. Neurochem. 2007, 101:709-717.
4. Chalimoniuk M., Langfort J. The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem. Int. 2007, 50:821-833.
5. Chu Y.P., Dodiya H., Aebischer P., Olanow C.W., Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 2009, 35:385-398.
6. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
7. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
8. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
9. Dalfo E., Gomez-Isla T., Rosa J.L., Bodelon M.N., Tejedor M.C., Barrachina M., et al. Abnormal alpha-synuclein interactions with rab proteins in alpha-synuclein A30P transgenic mice. J. Neuropathol. Exp. Neurol. 2004, 63:302-313.
10. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14524-14529.
11. Eberhardt O., Coelln R.V., Kugler S., Lindenau J., Rathke-Hartlieb S., Gerhardt E., et al. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 2000, 20:9126-9134.
12. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 2005, 252:37-42. Parkinson Study G.
13. Fahn S., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
14. Galvin J.E. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. (Berl) 2006, 112:115-126.
15. Gevaerd M.S., Miyoshi E., Silveira R., Canteras N.S., Takahashi R.N., Da Cunha C. L-dopa restores striatal dopamine level but fails m to reverse MPTP-induced memory deficits in rats. Int. J. Neuropsychopharmacol. 2001, 4:361-370.
16. Guo J.T., Chen A.Q., Kong Q., Zhu H., Ma C.M., Qin C. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell. Mol. Neurobiol. 2008, 28:35-47.
17. Hardy J., Lewis P., Revesz T., Lees A., Paisan-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Dev. 2009, 19:254-265.
18. Hellal F., Hurtado A., Ruschel J., Flynn K.C., Laskowski C.J., Umlauf M., et al. Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury. Science 2011, 331:928-931.
19. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20:6365-6373.
20. Kahle P.J., Haass C., Kretzschmar H.A., Neumann M. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J. Neurochem. 2002, 82:449-457.
21. Karpinar D.P., Balija M.B.G., Kugler S., Opazo F., Rezaei-Ghaleh N., Wender N., et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 2009, 28:3256-3268.
22. Kowsky S., Poppelmeyer C., Kramer E.R., Falkenburger B.H., Kruse A., Klein R., et al. RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20049-20054.
23. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 2001, 30:924-931.
24. Lee H.J., Khoshaghideh F., Lee S., Lee S.J. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci. 2006, 24:3153-3162.
25. Lee J., Zhu W.M., Stanic D., Finkelstein D.I., Horne M.H., Henderson J., et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008, 131:1574-1587.
26. Levy O.A., Malagelada C., Greene L.A. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009, 14:478-500.
27. Mitsumoto Y., Watanabe A., Mori A., Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 1998, 248:660-663.
28. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
29. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20:3214-3220.
30. Norris E.H., Giasson B.I., Hodara R., Xu S.H., Trojanowski J.Q., Ischiropoulos H., et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 2005, 280:21212-21219.
31. Oksman M., Tanila H., Yavich L. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of L-DOPA. Neuropharmacology 2009, 56:647-652.
32. Palkovits M., Brownstein M.J. Maps and Guide to Microdissection of the Rat Brain 1988, Elsevier Science Publishing Co, New York.
33. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
34. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F.L., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22:3090-3099.
35. Perlson E., Maday S., Fu M.M., Moughamian A.J., Holzbaur E.L. Retrograde axonal transport: pathways to cell death?. Trends Neurosci. 2010, 33:335-344.
36. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 2001, 77:1181-1184.
37. Saha A.R., Hill J., Utton M.A., Asuni A.A., Ackerley S., Grierson A.J., et al. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 2004, 117:1017-1024.
38. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C-T method. Nat. Protoc. 2008, 3:1101-1108.
39. Sidhu A., Wersinger C., Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 2004, 18:637-647.
40. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
41. Sousa V.L., Bellani S., Giannandrea M., Yousuf M., Valtorta F., Meldolesi J., et al. Alpha-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell 2009, 20:3725-3739.
42. Suenaga T., Hirano A., Llena J.F., Yen S.H., Dickson D.W. Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's-disease. Acta Neuropathol. (Berl) 1990, 80:280-286.
43. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson's disease. Mov. Disord. 2010, 25:S27-S31.
44. Szego E.M., Barabas K., Balog J., Szilagyi N., Korach K.S., Juhasz G., et al. Estrogen induces estrogen receptor alpha-dependent cAMP response element-binding protein phosphorylation via mitogen activated protein kinase pathway in basal forebrain cholinergic neurons in vivo. J. Neurosci. 2006, 26:4104-4110.
45. Szego E.M., Csorba A., Janáky T., Kékesi K.A., Abrahám I.M., Mórotz G.M., et al. Effects of estrogen on beta-amyloid-induced cholinergic cell death in the nucleus basalis magnocellularis. Neuroendocrinology 2011, 93:90-105.
46. Woods W.S., Boettcher J.M., Zhou D.H., Kloepper K.D., Hartman K.L., Ladror D.T., et al. Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J. Biol. Chem. 2007, 282:34555-34567.
47. Xu J., Kao S.Y., Lee F.J.S., Song W.H., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8:600-606.
48. Yang M.L., Hasadsri L., Woods W.S., George J.M. Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons. Mol. Neurodegener. 2010, 5.
49. Yu S., Ueda K., Chan P. Alpha-synuclein and dopamine metabolism. Mol. Neurobiol. 2005, 31:243-254.
50. Yu S., Li X., Liu G., Han J., Zhang C., Li Y., et al. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007, 145:539-555.